[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Egyéb

• Participants will be excluded if they did not meet any of the inclusion criteria or institutional requirements for participation.
• Did not meet all inclusion criteria.
• Did not undergo [18F]FET PET imaging as part of routine clinical care.
• Imaging data or associated clinical information is incomplete, non-evaluable, or of insufficient quality for analysis.
• Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.

• Signed patient informed consent with secondary use of data permitted. Pediatric patients (<18 years of age) will provide assent along with parental/legal guardian /caregiver consent
• Male or Female of any age at the time of [18F]FET PET imaging. While there is no age restriction, it is expected that enrollment of patients ≤ 3 years old will be rare due to the very low incidence of glioma in this age group.
• Documented histologic diagnosis or clinical suspicion of glioma (Grades 1-4) based on local clinical assessment.
• Underwent [18F]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy).
• Evidence of radiographic suspicion of recurrence or progression on MRI at the time of [18F]FET PET imaging.
• The adult patient, 18 years of age or older, has received nominal injected dose of 4 to 7 mCi (148 - 259 MBq ) of [18F]FET per imaging time point.
• The pediatric patients, 0-17 years old, must have received a pediatric dose adjusted based upon the patient's body weight.